First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

2023273 citationsJournal Articlegreen Open Access

Authors

Barbara Eichhorst · University of Cologne

Carsten Utoft Niemann · Copenhagen University Hospital

Arnon P. Kater · University Medical Center

Moritz Fürstenau · University of Cologne

Julia von Tresckow · Düsseldorf University Hospital

Can Zhang · University of Cologne

Sandra Robrecht

Abstract

Venetoclax-obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA-CLL13 ClinicalTrials.gov number, NCT02950051; EudraCT number, 2015-004936-36.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 19, pp. 1739-1754

DOI: 10.1056/nejmoa2213093

Field-Weighted Citation Impact: 77.98